Promising anti-cancer activity in experimental drug: Next-gen melanoma drug, TAK-733, excels in lab tests
“The importance of this molecule is that it’s a next-generation and highly potent inhibitor of a known melanoma pathway. It was highly effective against melanoma and the method of our study — using patient-derived tumor samples grown in mice — makes us especially optimistic that we should see similar results in the human disease,” says John Tentler, PhD, investigator at the CU Cancer Center, associate professor at CU School of Medicine and one of the paper’s lead authors…